3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
111
Neoplasm Metastasis
9
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms, Male
3
Breast Diseases
3
Obesity
2
Multiple Endocrine Neoplasia Type 1
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Arthralgia
2
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Sleep Wake Disorders
1
Skin Diseases
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Primary Breast Cancer ER+ve
1
Post Menopausal Women With Early Breast Cancer
1
Patient Acceptance of Health Care
1
Pain
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Metastatic Beast Cancer
1
Mammary Neoplasms, Animal
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
Interventions
Gefitinib
3
Erlotinib Hydrochloride
3
sotorasib
1
pralsetinib
1
osimertinib
1
ficlatuzumab
1
exemestane
1
entinostat
1
durvalumab
1
cobimetinib
1
camrelizumab
1
Tyrosine Kinase Inhibitors
1
Radiosurgery
1
Prednisone
1
Pemetrexed
1
Leuprolide
1
Dasatinib
1
Carboplatin
1
Afatinib
1
AZD3759
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Respiratory Tract Diseases
×
exemestane
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled